Inspire Investing LLC Acquires 9,484 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Inspire Investing LLC increased its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 44.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,792 shares of the company’s stock after acquiring an additional 9,484 shares during the quarter. Inspire Investing LLC’s holdings in Syndax Pharmaceuticals were worth $407,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Simplify Asset Management Inc. raised its position in shares of Syndax Pharmaceuticals by 62.5% during the third quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company’s stock valued at $2,352,000 after buying an additional 46,992 shares during the last quarter. Franklin Resources Inc. raised its holdings in Syndax Pharmaceuticals by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock valued at $34,948,000 after acquiring an additional 208,043 shares in the last quarter. State Street Corp raised its holdings in Syndax Pharmaceuticals by 4.1% in the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company’s stock valued at $72,588,000 after acquiring an additional 148,491 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Syndax Pharmaceuticals by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company’s stock worth $13,397,000 after acquiring an additional 41,458 shares during the period. Finally, Barclays PLC increased its position in shares of Syndax Pharmaceuticals by 143.4% during the third quarter. Barclays PLC now owns 187,629 shares of the company’s stock valued at $3,612,000 after purchasing an additional 110,535 shares during the period.

Syndax Pharmaceuticals Price Performance

SNDX stock opened at $14.25 on Friday. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -3.93 and a beta of 0.89. The business has a fifty day moving average price of $14.39 and a 200 day moving average price of $18.07. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $12.06 and a fifty-two week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period in the prior year, the firm earned ($0.73) earnings per share. On average, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -3.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on SNDX. Scotiabank reduced their target price on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th. Stifel Nicolaus upped their target price on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, October 14th. StockNews.com cut shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. Finally, JPMorgan Chase & Co. upped their price objective on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.20.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).